[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
September 20, 2010

Effectiveness of Infliximab for Intralymphatic Histiocytosis With Rheumatoid Arthritis

Author Affiliations

Author Affiliations: Division of Dermatology, Department of Internal Related (Drs Sakaguchi, Nagai, and Nishigori), and Division of Clinical Pathology and Immunology, Department of Internal Medicine (Drs Tsuji, Morinobu, and Kumagai), Kobe University Graduate School of Medicine, Kobe, Japan.

Arch Dermatol. 2011;147(1):131-133. doi:10.1001/archdermatol.2010.407

A 66-year-old woman was seen with a 2-year history of a reddish-brown plaque on her right elbow. She had a history of rheumatoid arthritis (RA) for about 8 years and was referred to our hospital for consultation regarding the skin lesion. Physical examination revealed a reddish-brown plaque with edema on her right elbow (Figure 1A). The joint underlying the skin lesion was painful. Abnormal laboratory levels included C-reactive protein (CRP), 4.04 mg/dL; anticyclic citrullinated peptide antibodies, 156.8 U/mL (normal, <4.5 U/mL); matrix metalloproteinase-3, 467.0 ng/mL (normal range, 17.3-59.7 ng/mL); rheumatoid factor, 56 IU/mL (normal, <20 IU/mL). Her DAS28-CRP score (disease activity score of 28 joints using CRP) was 3.22. (To convert C-reactive protein to nanomoles per liter, multiply by 9.524.)

First Page Preview View Large
First page PDF preview
First page PDF preview
×